Paper41459535
Evaluation of programmed cell death ligand-1 expression in primary central nervous system lymphoma using whole-tumor histogram analysis of multiparametric MRI: implications for immunotherapy selection.
Zhou X and 10 others. Front Immunol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Evaluation of programmed cell death ligand-1 expression in primary central nervous system lymphoma using whole-tumor histogram analysis of multiparametric MRI: implications for immunotherapy selection. Papers, record 41459535. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41459535
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Evaluation of programmed cell death ligand-1 expression in primary central nervous system lymphoma using whole-tumor histogram analysis of multiparametric MRI: implications for immunotherapy selection.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| B7-H1 Antigen | Major topic |
| Central Nervous System Neoplasms | Major topic |
| Multiparametric Magnetic Resonance Imaging | Major topic |
| Lymphoma | Major topic |
| Humans | |
| Male | |
| Middle Aged | |
| Aged | |
| Female | |
| Adult | |
| Aged, 80 and over | |
| Young Adult | |
| Immunotherapy | |
| ROC Curve | |
| Biomarkers, Tumor |
Source PubMed
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34976829 | Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics. | Front Oncol | 2021 | https://conductscience.org/library/papers/34976829 | PubMed |
| 2 | 30917792 | The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. | BMC Cancer | 2019 | https://conductscience.org/library/papers/30917792 | PubMed |
| 3 | 38637428 | Association between programmed cell death ligand-1 expression in patients with cervical cancer and apparent diffusion coefficient values: a promising tool for patient´s immunotherapy selection. | Eur Radiol | 2024 | https://conductscience.org/library/papers/38637428 | PubMed |
| 4 | 39187807 | Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study. | BMC Med Imaging | 2024 | https://conductscience.org/library/papers/39187807 | PubMed |
| 5 | 37926648 | Relationships between intravoxel incoherent motion parameters and expressions of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) in patients with cervical cancer. | Clin Radiol | 2024 | https://conductscience.org/library/papers/37926648 | PubMed |
| 6 | 36428726 | Correlation between PD-L1 Expression of Non-Small Cell Lung Cancer and Data from IVIM-DWI Acquired during Magnetic Resonance of the Thorax: Preliminary Results. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36428726 | PubMed |
| 7 | 26239088 | Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. | Blood | 2015 | https://conductscience.org/library/papers/26239088 | PubMed |
| 8 | 39225608 | Use of Pretreatment Perfusion MRI-based Intratumoral Heterogeneity to Predict Pathologic Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. | Radiology | 2024 | https://conductscience.org/library/papers/39225608 | PubMed |
| 9 | 28356247 | PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. | Blood | 2017 | https://conductscience.org/library/papers/28356247 | PubMed |
| 10 | 32382113 | Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma? | Br J Cancer | 2020 | https://conductscience.org/library/papers/32382113 | PubMed |
| 11 | 33764703 | Relationships between apparent diffusion coefficient (ADC) histogram analysis parameters and PD-L 1-expression in head and neck squamous cell carcinomas: a preliminary study. | Radiol Oncol | 2021 | https://conductscience.org/library/papers/33764703 | PubMed |
| 12 | 32086577 | MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. | Eur Radiol | 2020 | https://conductscience.org/library/papers/32086577 | PubMed |
| 13 | 36060584 | Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and 18F-FDG PET. | Quant Imaging Med Surg | 2022 | https://conductscience.org/library/papers/36060584 | PubMed |
| 14 | 34679573 | Assessing PD-L1 Expression Level via Preoperative MRI in HCC Based on Integrating Deep Learning and Radiomics Features. | Diagnostics (Basel) | 2021 | https://conductscience.org/library/papers/34679573 | PubMed |
| 15 | 39227388 | Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39227388 | PubMed |
| 16 | 28693793 | Biomarkers of response to PD-1/PD-L1 inhibition. | Crit Rev Oncol Hematol | 2017 | https://conductscience.org/library/papers/28693793 | PubMed |
| 17 | 33299660 | Co-localization of CD169+ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression. | Oncoimmunology | 2020 | https://conductscience.org/library/papers/33299660 | PubMed |
| 18 | 33239315 | Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers. | ESMO Open | 2020 | https://conductscience.org/library/papers/33239315 | PubMed |
| 19 | 34699590 | Primary central nervous system lymphoma. | Blood | 2022 | https://conductscience.org/library/papers/34699590 | PubMed |
| 20 | 25943068 | Programmed cell death-1 inhibition in lymphoma. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25943068 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42137157 | Whole-volume apparent diffusion coefficient histogram analysis for prediction of programmed cell death ligand 1 expression in periampullary carcinomas: a preliminary study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42137157 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41459535
GET https://conductscience.org/api/papers/v1/41459535/references?page=2